MC Healthcare Ventures — Full Portfolio
45 tracked investments · listed companies and verified rows first
Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.
BiotechHealthtechCambridge, US
Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)Ommer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)in
BoardJean-Francois Formela(Director)in
Co-investorsAtlas VentureNew Enterprise Associates (NEA)
Discovers and develops microRNA-targeting therapies for areas of high unmet medical need.
BiotechBoulder, US
William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)David Rodman(Executive Officer)Jason Leverone(Executive Officer)Christopher J Morl(Executive Officer)Christopher Bowden(Director)
Co-investorsBrace PharmaBoulder Ventures
BiotechLondon
James Ede-Golightly(Director)Alistair Gray(Director)Craig Tooman(Executive Officer)Dave Lemus(Director)Giles Campion(Executive Officer)Romano Steven(Director)
Co-investorsForesite CapitalNextech InvestVivo Capital
A venture studio embedded within Alloy Therapeutics that partners with academics, entrepreneurs, pharma companies, and VCs to create and develop early-stage drug discovery companies.
BiotechDeep TechWaltham, US
Errik B. Anderson(Executive Officer, Director)inPiotr Bobrowicz(Executive Officer, Director)inJay Rosanelli(Executive Officer)in
BoardAnthony Sun(Director)Ulrik Nielsen(Director)in
Board seatAlaa Halawa· per SEC Form D · $40M raise · filed Apr 2026
Co-investors82VS8VCJIC Venture Growth InvestmentsMission Biocapital
Innovaccer offers Provider Copilot, an AI assistant that automates clinical documentation, pre-visit prep, medical scribing, and prior authorization workflows for healthcare providers and care teams.
AI & Machine LearningData & InfrastructureDigital HealthHealthtechSan Francisco, US
Wendy Rubas(Chief Legal and Compliance Officer of the Issuer)Abhinav Shashank(Chief Executive Officer and Director of the Issuer)Glenn Steele(Director of the Issuer)Sumir Chadha(Director of the Issuer)Sandeep Gupta(Chief Operations Officer and Director of the Issuer)Scott Bruckner(Chief Financial Officer of the Issuer)
Board seatAlaa Halawa· per SEC Form D · filed Oct 2025
Co-investors500 GlobalB Capital GroupB4 CapitalM12 (Microsoft's Venture Fund)OMERS Private Equity Inc.Steadview Capital+5 more
A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.
BiotechAustin, US
Jason Ehrlich(Executive Officer, Director)
BoardTravis Murdoch(Director)Fred Cohen(Director)Cariad Chester(Director)Paul Berns(Director)
Board seatAlaa Halawa· per SEC Form D · $330M raise · filed Jun 2026
Co-investorsMonograph Capital PartnersARCH Venture PartnersTCG Crossover
BiotechHealthtechDurham, US
Xiling Shen(Executive Officer, Director, Promoter)David Shiaowen(Director)William Roy Smythe(Executive Officer, Director)
BoardJohn de Koning(Director)
Board seatAlaa Halawa· per SEC Form D · $19.4M raise · filed Apr 2025
Spin-out of Forge Therapeutics pioneering a metalloenzyme chemistry platform for immuno-oncology and inflammation medicines.
Blacksmith Medicines discovers and develops small molecule inhibitors of metal-dependent enzymes for oncology and infectious disease applications.
BiotechDeep TechMedical Devices
Zachary Zimmerman(CEO)
Capsigen engineers customized AAV (adeno-associated virus) capsids using its proprietary Transcription-Dependent Directed Evolution (TRADE) screening platform and data science to deliver gene therapies to specific target cells.
AI & Machine LearningBiotechHealthtechVancouver, US
John(Chief Executive Officer)inCharlie(Chief Business Officer)in
Developed next-generation protein drugs for inflammatory diseases and cancer; acquired by J&J in 2014.
Co-investorsAndera PartnersSeroba Life Sciences
Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies.
BiotechDeep TechMedical DevicesCopenhagen, DK
Simon Glerup(Professor)Camilla Gustafsen(Professor)Peder Søndergaard Madsen(Professor)Peter Seeberger(Professor)
Co-investorsGilde HealthcareInkef
Developed RNA/DNA editing technology using PPR proteins for pharma, agriculture, and biomanufacturing.
Co-investorsAtlas Venture
Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.
BiotechSan Carlos, US
Hugh Y. Rienhoff, Jr., M.D.(Executive Officer, Director)
BoardMarten Steen(Director)Dennis Henner, Ph.D.(Director)Bryant E. Fong(Director)
Forge Therapeutics operates a drug discovery platform focused on developing medicines that target human metalloenzymes.
BiotechDeep Tech
Genkyotex was a developer of NOX inhibitor therapeutics, now owned by Calliditas Therapeutics AB.
Biotech
Co-investorsAndera PartnersVesalius Biocapital Partners
Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.
BiotechCambridge, US
Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)Michael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Thomas Davis(Executive Officer)
Co-investorsCycad Group LLCLux CapitalAdvent Life SciencesNew Enterprise Associates (NEA)
Developed RNAi therapeutics; merged with Silence Therapeutics in December 2009.
Outrun Therapeutics is a preclinical biotech developing small molecule E3 ligase inhibitors to stabilise tumour suppressor proteins for treating cancer and other diseases.
BiotechDeep TechDundee, GB
Satpal Virdee(Founder)
Co-investorsM Ventures
PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address.
AI & Machine LearningBiotechDeep Tech
Co-investorsCambridge Angels groupMartlet CapitalO2h VenturesWren Capital
Diagnostics company focused on low-abundance protein biomarkers; merged with a Biocartis division to form MyCartis in 2014.
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsDroia VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health InvestorsAmgen Ventures+6 more
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
BoardMike Dial(Director)in
Co-investorsIllumina VenturesM VenturesPappas CapitalSV Health InvestorsDementia Discovery FundHatteras Venture Partners+1 more
Biopharmaceutical company targeting RIG-I for immune-mediated treatment of cancer and viral diseases; acquired by Merck in 2017.
Co-investorsSunstone Capital
Uses its JUMP70 chaperone platform to develop therapeutics for neurodegenerative diseases like ALS and Huntington's.
SOLA Biosciences is a preclinical-stage biopharmaceutical company developing gene therapies for neurodegenerative diseases like ALS, Huntington's Disease, and Alzheimer's Disease by targeting misfolded proteins.
BiotechDeep TechMedical DevicesBoston, US
Keizo Koya(Founder and CEO)Akinori Hishiya(Founder and CSF)
Co-investorsEisai Innovation, Inc.UTEC
Developing a voice-based technology platform to monitor and diagnose psychological and physical conditions.
Sonde develops voice-based biomarker technology to detect health conditions early through analysis of speech patterns on everyday devices.
AI & Machine LearningDigital HealthHealthtech
David Liu(Chief Executive Officer)James Harper(Chief Strategy Officer)Yogendra Jain(Chief Technology Officer)Erik Larsen(Senior Vice President, Clinical Development & Customer Success)Sanjay Pothen(Chief Financial Officer)Garrett Bussiere(Vice President of Strategic Partnerships)
Co-investorsEvidity Health CapitalM Ventures
Developed drugs targeting the interface between inflammatory and metabolic pathways via adaptive ER responses.
Clinical-stage company developing targeted therapies for kidney disease.
Co-investorsPappas Capital
Developed a novel TPD technology for selective degradation of aggregated proteins in neurodegenerative disease.
LiberoThera is a drug discovery company using cell-free membrane protein preparation technology and non-natural amino acid incorporation technology to develop antibody-based therapeutics, including antibodies targeting GPCRs such as anti-CCR8.
BiotechDeep Tech
Co-investorsTaiho Ventures, LLCUTokyo Innovation Platform Co. Ltd.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.